ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Drug resistance to tyrosine kinase inhibitors (TKIs), due to BCR::ABL1 mutations and residual leukemia stem cells (LSCs), remains a major challenge in CML treatment.